Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;93(7):686-692.
doi: 10.1136/jnnp-2021-328338. Epub 2022 May 4.

Antithrombotic therapy in the postacute phase of cervical artery dissection: the Italian Project on Stroke in Young Adults Cervical Artery Dissection

Affiliations

Antithrombotic therapy in the postacute phase of cervical artery dissection: the Italian Project on Stroke in Young Adults Cervical Artery Dissection

Debora Pezzini et al. J Neurol Neurosurg Psychiatry. 2022 Jul.

Abstract

Objective: To explore the impact of antithrombotic therapy discontinuation in the postacute phase of cervical artery dissection (CeAD) on the mid-term outcome of these patients.

Methods: In a cohort of consecutive patients with first-ever CeAD, enrolled in the setting of the multicentre Italian Project on Stroke in Young Adults Cervical Artery Dissection, we compared postacute (beyond 6 months since the index CeAD) outcomes between patients who discontinued antithrombotic therapy and patients who continued taking antithrombotic agents during follow-up. Primary outcome was a composite of ischaemic stroke and transient ischaemic attack. Secondary outcomes were (1) Brain ischaemia ipsilateral to the dissected vessel and (2) Recurrent CeAD. Associations with the outcome of interest were assessed by the propensity score (PS) method.

Results: Of the 1390 patients whose data were available for the outcome analysis (median follow-up time in patients who did not experience outcome events, 36.0 months (25th-75th percentile, 62.0)), 201 (14.4%) discontinued antithrombotic treatment. Primary outcome occurred in 48 patients in the postacute phase of CeAD. In PS-matched samples (201 vs 201), the incidence of primary outcomes among patients taking antithrombotics was comparable with that among patients who discontinued antithrombotics during follow-up (5.0% vs 4.5%; p(log rank test)=0.526), and so was the incidence of the secondary outcomes ipsilateral brain ischaemia (4.5% vs 2.5%; p(log rank test)=0.132) and recurrent CeAD (1.0% vs 1.5%; p(log rank test)=0.798).

Conclusions: Discontinuation of antithrombotic therapy in the postacute phase of CeAD does not appear to increase the risk of brain ischaemia during follow-up.

Keywords: CEREBROVASCULAR DISEASE; CLINICAL NEUROLOGY; STROKE.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AZ reports personal fees from Boehringer-Ingelheim, personal fees from Medtronic, personal fees from Cerenovus, and personal fees from Stryker outside the submitted work. CL reports personal fees from Daiichi Sankio, personal fees from Boehringer Ingelheim, and personal fees from Bayer Healthcare outside the submitted work. MP reports Bayer speaker bureau, Boerinhger speaker bureau, Pfizer speaker bureau, Daiiki Sankyo speaker bureau, BMS speaker bureau, Sanofi speaker bureau, the Italian Ministry of Heatlh Ricerca Corrente – IRCCS MultiMedica.

Publication types

MeSH terms

Substances

LinkOut - more resources